142 - New Gains in Weight Loss Pharmacotherapy
HelixTalk - Rosalind Franklin University's College of Pharmacy Podcast
Sean P. Kane, PharmD, BCPS
5 • 644 Ratings
🗓️ 18 January 2022
⏱️ 47 minutes
🧾️ Download transcript
Summary
In this episode, we will build up on our previous Weight loss Pharmacotherapy Episode, episode #13 to discuss updates in guidelines, prevention of obesity from comorbidity standpoint, and new treatment agents for weight-loss with a particular focus on Contrave (naltrexone/bupropion), Saxenda (liraglutide), and Wegovy (semaglutide).
Transcript
Click on a timestamp to play from that location
| 0:00.0 | Welcome to Helix Talk, an educational podcast for healthcare students and providers covering real-life clinical pearls, professional pharmacy topics, and drug therapy discussions. |
| 0:11.0 | This podcast is provided by pharmacists and faculty members at Rosal Franklin University College of Pharmacy. |
| 0:17.0 | This podcast contains general information for educational purposes only. This is not |
| 0:22.0 | professional advice and should not be used in lieu of obtaining advice from a qualified |
| 0:26.0 | health care provider. And now on to the show. Welcome to Healot's Talk episode 142. I'm your |
| 0:34.3 | co-host Dr. Kane. I'm Dr. Patel and today with us back is Dr. Stravastov. Thank you for |
| 0:40.6 | being back with us, Dr. Stravastva. Thanks for having me join you. I'm very excited to talk about |
| 0:45.7 | this very important topic. And that said, the title of our episode today is New Gains in |
| 0:52.4 | Weight Loss Pharmacotherapy. And so just to remind our audience, |
| 0:57.5 | we did record a very long time ago, episode 13, about pharmacotherapy of weight loss medications. |
| 1:04.0 | Since then, Belweek, Lorcasarin, which was the 5-HD2 receptor agonist, has been pulled out of the market. |
| 1:13.7 | They're reciting some malignancy concerns. |
| 1:16.6 | The kuzmia, which is a combination of fentermin and topiramate, the over-the-counter ally, |
| 1:23.1 | or aostat, or prescription, zanical, as well as the short-term therapy with fentermine the adipax |
| 1:30.3 | is still available in the market since then we have a few new agents and so we figured it will |
| 1:35.9 | be nice to talk about those agents they definitely have made some stirred lately in the news market |
| 1:43.2 | as well so figured we can talk about that, |
| 1:46.0 | along with some guideline updates, which were long due. And so for that, we have Dr. Shavasva with us. |
| 1:51.9 | So Dr. Shabasava, can you kind of just lay out the background and tell us what obesity is really? |
| 1:58.7 | Definitely. So obesity is something, you know, that we have known about for a very |
| 2:04.9 | long time, but it's taken also a long time to truly see it as it is currently defined, you know, |
| 2:13.2 | as a chronic and progressive disease, just like any other chronic condition that's there. |
... |
Please login to see the full transcript.
Disclaimer: The podcast and artwork embedded on this page are from Sean P. Kane, PharmD, BCPS, and are the property of its owner and not affiliated with or endorsed by Tapesearch.
Generated transcripts are the property of Sean P. Kane, PharmD, BCPS and are distributed freely under the Fair Use doctrine. Transcripts generated by Tapesearch are not guaranteed to be accurate.
Copyright © Tapesearch 2025.